A Phase III, Randomized, Non-Inferiority Study Comparing the Efficacy and Safety of Biosimilar Filgrastim Versus Originator Filgrastim for Chemotherapy-Induced Neutropenia in Breast Cancer Patients . Clinics 2016, 71 (10), 586-592. https://doi.org/10.6061/clinics/2016(10)06.